...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: How & who comes up with valuations?
Reply New Message
Back To Forum List View
How & who comes up with valuations?
1
fuzzyjr
Apr 17, 2024 10:25AM
Re: How & who comes up with valuations?
2
fuzzyjr
Apr 17, 2024 11:21AM
Re: How & who comes up with valuations?
2
KOO-KOO2
Apr 17, 2024 01:27PM
Re: How & who comes up with valuations?
2
fuzzyjr
Apr 17, 2024 01:36PM
Re: How & who comes up with valuations?
2
fuzzyjr
Apr 17, 2024 01:41PM
Re: How & who comes up with valuations?
1
KOO-KOO2
Apr 17, 2024 01:57PM
Re: How & who comes up with valuations?
1
fuzzyjr
Apr 17, 2024 03:56PM

I believe the Alpine drug passed Phase 11. Phase 111 is scheduled for H2/2024.

I'm not aware that Zenith has proof of success. ZEN-3694 to my understanding passed a Phase 1 safety profile, for mCRPC. (reference Oct 26, 2023 AGM)

 

Koo

1 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply